These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 2571967)

  • 41. Effect of new quaternary bisammonium compounds on the growth and cell surface hydrophobicity of Enterobacter cloacae.
    Majtán V; Majtánová L
    Cent Eur J Public Health; 2000 May; 8(2):80-2. PubMed ID: 10857043
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [In vitro effect of quinolones on the hydrophobicity of Acinetobacter baumannii].
    Hostacká A
    Ceska Slov Farm; 1999 Nov; 48(6):272-5. PubMed ID: 10748745
    [TBL] [Abstract][Full Text] [Related]  

  • 43. NMR studies of interactions between periplasmic chaperones from uropathogenic E. coli and pilicides that interfere with chaperone function and pilus assembly.
    Hedenström M; Emtenäs H; Pemberton N; Aberg V; Hultgren SJ; Pinkner JS; Tegman V; Almqvist F; Sethson I; Kihlberg J
    Org Biomol Chem; 2005 Dec; 3(23):4193-200. PubMed ID: 16294247
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bacterial behaviors on polymer surfaces with organic and inorganic antimicrobial compounds.
    Ji J; Zhang W
    J Biomed Mater Res A; 2009 Feb; 88(2):448-53. PubMed ID: 18306288
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Influence of sub-inhibitory concentrations of antibacterials on the surface properties and adhesion of Escherichia coli.
    Loubeyre C; Desnottes JF; Moreau N
    J Antimicrob Chemother; 1993 Jan; 31(1):37-45. PubMed ID: 8444673
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antibacterial activity of nitroxoline and sulphamethizole alone and in combination in urinary tract infections.
    Jacobs MR; Robinson RG; Koornhof HJ
    S Afr Med J; 1978 Dec; 54(23):959-62. PubMed ID: 106479
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antibacterial and antifungal activities of nitroxoline Mannich bases.
    Medić-Sarić M; Maysinger D; Movrin M; Dvorzak I
    Chemotherapy; 1980; 26(4):263-7. PubMed ID: 6771105
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of iron on adhesion of urinary Escherichia coli.
    Sharma MB; Sharma S; Sharma BK
    Indian J Med Res; 1988 Jun; 87():561-4. PubMed ID: 2907325
    [No Abstract]   [Full Text] [Related]  

  • 49. Repurposing of the antibiotic nitroxoline for the treatment of mpox.
    Bojkova D; Zöller N; Tietgen M; Steinhorst K; Bechtel M; Rothenburger T; Kandler JD; Schneider J; Corman VM; Ciesek S; Rabenau HF; Wass MN; Kippenberger S; Göttig S; Michaelis M; Cinatl J
    J Med Virol; 2023 Mar; 95(3):e28652. PubMed ID: 36897017
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Rationally repurposed nitroxoline inhibits preclinical models of Epstein-Barr virus-associated lymphoproliferation.
    Ibáñez de Garayo M; Liu W; Rondeau NC; Damoci CB; Miranda JJL
    J Antibiot (Tokyo); 2021 Oct; 74(10):763-766. PubMed ID: 34163027
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Synthesis and evaluation of a large library of nitroxoline derivatives as pancreatic cancer antiproliferative agents.
    Veschi S; Carradori S; De Lellis L; Florio R; Brocco D; Secci D; Guglielmi P; Spano M; Sobolev AP; Cama A
    J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1331-1344. PubMed ID: 32588672
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Novel mechanism of cathepsin B inhibition by antibiotic nitroxoline and related compounds.
    Mirković B; Renko M; Turk S; Sosič I; Jevnikar Z; Obermajer N; Turk D; Gobec S; Kos J
    ChemMedChem; 2011 Aug; 6(8):1351-6. PubMed ID: 21598397
    [No Abstract]   [Full Text] [Related]  

  • 53. Integrative proteomic and functional analyses provide novel insights into the action of the repurposed drug candidate nitroxoline in AsPC-1 cells.
    Veschi S; Ronci M; Lanuti P; De Lellis L; Florio R; Bologna G; Scotti L; Carletti E; Brugnoli F; Di Bella MC; Bertagnolo V; Marchisio M; Cama A
    Sci Rep; 2020 Feb; 10(1):2574. PubMed ID: 32054977
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antimicrobial activity of clioquinol and nitroxoline: a scoping review.
    Wykowski R; Fuentefria AM; de Andrade SF
    Arch Microbiol; 2022 Jul; 204(8):535. PubMed ID: 35907036
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sensitivity of bacterial coaggregation to chelating agents.
    Taweechaisupapong S; Doyle RJ
    FEMS Immunol Med Microbiol; 2000 Aug; 28(4):343-6. PubMed ID: 10891659
    [TBL] [Abstract][Full Text] [Related]  

  • 56. High-performance liquid chromatographic analysis of nitroxoline in plasma and urine.
    Sorel RH; Snelleman C; Hulshoff A
    J Chromatogr; 1981 Feb; 222(2):241-8. PubMed ID: 7251741
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Selective inhibition mechanism of nitroxoline to the BET family: Insight from molecular simulations.
    Zhu M; Song LT; Liu RR; Zhai HL; Meng YJ; Ren CL
    Life Sci; 2021 Apr; 270():119141. PubMed ID: 33529672
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nitroxoline: repurposing its antimicrobial to antitumor application.
    Mitrović A; Kos J
    Acta Biochim Pol; 2019 Dec; 66(4):521-531. PubMed ID: 31834689
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Addition of 2-(ethylamino)acetonitrile group to nitroxoline results in significantly improved anti-tumor activity
    Mitrović A; Sosič I; Kos Š; Tratar UL; Breznik B; Kranjc S; Mirković B; Gobec S; Lah T; Serša G; Kos J
    Oncotarget; 2017 Aug; 8(35):59136-59147. PubMed ID: 28938624
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Preclinical pharmacodynamic evaluation of antibiotic nitroxoline for anticancer drug repurposing.
    Zhang QI; Wang S; Yang D; Pan K; Li L; Yuan S
    Oncol Lett; 2016 May; 11(5):3265-3272. PubMed ID: 27123101
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.